Ki67 index importance in patients with breast cancer
DOI:
https://doi.org/10.12775/JEHS.2024.75.60763Keywords
tumor marker Ki-67, neoadjuvant therapy, proliferation marker, immunohistochemical studyAbstract
Breast cancer oncosurgery in its therapeutic and diagnostic strategies largely bases upon a considerable spectrum of laboratory findings. In the following article is presented a deep analysis of the series of studies devoted to the importance of oncological markers in practice, the necessity in proliferative activity index of the tumor to be determined, the diagnostic value of Ki-67 marker expression level for solving such tasks as evaluation of malignancy, selection of the best treatment strategy, adjuvant or neoadjuvant therapy, as well as the medical intervention results evaluation. On the grounds of the results, conclusions regarding the importance of determining the Ki-67 marker expression level as a comprehensive part of breast cancer diagnostics, the choice of proper treatment strategy and estimation of the one were made.
References
1. Moroz VM, Shandra OA, Vastyanov RS, Yoltukhivsky MV, Omelchenko OD. Physiology. Vinnytsia: Nova Knyha. 2016. 722.
2. Dressler LG, Seamer L, Owens MA, Clark GM, McGuire WL. Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry. Cancer Res. 1987; 47(20): 5294-5302.
3. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984; 133(4): 1710–1715.
4. Yerushalmi R, Woods R, Ravdin PM , Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11(2): 174-183. doi: 10.1016/S1470-2045(09)70262-1
5. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005; 23(28): 7212–7220.
6. Harris L., Fritsche H., Mennel R., Norton L, Ravdin P, Taube S. et al. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33): 5287-5312. doi: 10.1200/JCO.2007.14.2364
7. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011; 29(32): 4273-4278. doi: 10.1200/JCO.2010.31.2835.
8. Penault-Llorca F., Andre F., Sagan C, Lacroix-Triki M, Denoux Y, Verriele V. et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009 Jun 10;27(17):2809-15. doi: 10.1200/JCO.2008.18.2808.
9. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009; 27(8): 1168-1176. doi: 10.1200/JCO.2008.18.1024
10. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M. et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008; 100(3): 207-212. doi: 10.1093/jnci/djm289.
11. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J. et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103(22): 1656–1664.
12. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C. et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005; 11(2): 951–958.
13. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F. et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003; 63(19): 6523–6531.
14. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS. et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008; 100(19): 1380-1388. doi: 10.1093/jnci/djn309
15. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R. et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007; 99(2): 167-170. doi: 10.1093/jnci/djk020
16. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton JH, Klijn JGM. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359(9324): 2131-2139. doi: 10.1016/s0140-6736(02)09088-8
17. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF. et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353(26): 2747-2757. doi: 10.1056/NEJMoa052258.
18. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A. et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011; 29(17): 2342-2349. doi: 10.1200/JCO.2010.31.6950
19. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT. et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013; 31(11): 1398-1404. doi: 10.1200/JCO.2012.44.7805
20. Guix M, Granja NM, Meszoely I, Adkins TB, Wieman BM, Frierson KE. et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol. 2008; 26(6): 897-906. doi: 10.1200/JCO.2007.13.5939.
21. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M. et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001; 61(18): 6739–6746.
22. Smith I.E., Walsh G., Skene A, Llombart A, Mayordomo JI, Detre S. et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007; 25(25): 3816-3822. doi: 10.1200/JCO.2006.09.6578.
23. Assersohn L, Salter J, Powles TJ, A'hern R, Makris A, Gregory RK. et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat. 2003; 82(2): 113-123. doi: 10.1023/B:BREA.0000003968.45511.3f.
24. Jones R.L., Salter J., A’Hern R, Nerurkar A, Parton M, Reis-Filho JS. et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009; 116(1): 53-68. doi: 10.1007/s10549-008-0081-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 O. Bondar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 47
Number of citations: 0
